

PAGE 1 of 1

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))	ATTY DOCKET NO.: 221.P1	SERIAL NO.: 08/900,746
	APPLICANT: Arimilli et al.	
	FILING DATE: 7/25/97	GROUP ART UNIT: 1613

U.S. PATENT DOCUMENTS

EXAMR'S INITIALS	PATENT NO.	ISSUE DATE	PATENTEE	CLASS/ SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMR'S INITIALS	PATENT NO.	PUBLICATION DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES/NO

OTHER DOCUMENTS

EXAMR'S INITIALS	ARTICLE
<i>mose</i>	Arimilli et al., "Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs", 8(6):557-567, ANTIVIRAL CHEM & CHEMO, 1997 ✓
<i>mose</i>	Arimilli et al., "Orally Bioavailable Acyclic Nucleoside Phosphonate Prodrugs: Adefovir Dipivoxil and Bis(POC)PMPA", Vol. 3 (accepted for publication), ADV ANTIVIRAL DRUG DESIGN, 1998 ✓
<i>mose</i>	Shaw et al., "Metabolism and Pharmacokinetics of Novel Oral Prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in Dogs", 14(12):1824-1829, PHARM RES, 1997 ✓

EXAMINER

Michael G. Ambrose

DATE CONSIDERED

4/13/98

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(37 CFR 1.98(b))</small>	ATTY DOCKET NO.: 221.P1 SERIAL NO.: 08/900,746	
	APPLICANT: Arimilli et al.	
	FILING DATE: 7/25/97	GROUP ART UNIT: 1205 1613

U.S. PATENT DOCUMENTS

EXAMR'S INITIALS	PATENT NO.	ISSUE DATE	PATENTEE	CLASS/ SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMR'S INITIALS	PATENT NO.	PUBLICATION DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES/NO

OTHER DOCUMENTS

EXAMR'S INITIALS	ARTICLE
msa	Ikeda et al., "Studies on Prodrugs. III. A Convenient and Practical Preparation of Ampicillin Prodrugs", 32:4316-4322, CHEM PHARM BULL, 1984
msa	Jones et al., "Minireview: nucleotide prodrugs", 27:1-17, ANTIVIRAL RES, 1995
msa	Krise et al., "Prodrugs of phosphates, phosphonates, and phosphinates", 19:287-310, Advanced Drug Delivery Reviews, 22-May-1996
msa	Landgrebe, John A., "Crystallization and Filtration", 3rd edition, pp. 65-77, Theory and Practice in the Organic Laboratory, 1982
msa	Starrett et al., "Synthesis, Oral Bioavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)eth]adenine (PMEA)", 37:1857-1864, J MED CHEM, 1994
msa	Tsai et al., "Effects of (R)-9-(2-Phosphonylmethoxypropyl)adenine Monotherapy on Chronic SIV Infection in Macaques", 13(8):707-712, AIDS RES & HUM RETRO, 1997
msa	Tsai et al., "Prevention of SIV Infection in Macaques by (R)-9-(2-Phosphonylmethoxypropyl)adenine", 270:1197-1199, SCIENCE, 17-Nov-1995

EXAMINER	Michael G. Ambrose	DATE CONSIDERED	4/11/98
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(37 CFR 1.98(b))</small>	ATTY DOCKET NO.: 221.P1 SERIAL NO.: 08/900,746
	APPLICANT: Arimilli et al.
	FILING DATE: 7/25/97 GROUP ART UNIT: <u>1613</u>

U.S. PATENT DOCUMENTS

EXAMR'S INITIALS	PATENT NO.	ISSUE DATE	PATENTEE	CLASS/ SUBCLASS	FILING DATE
<i>msla</i>	3,524,846	8/18/70	Moffatt et al.	—	6/2/67
<i>msla</i>	4,476,248	10/9/84	Gordon et al.	—	7/25/83
<i>msla</i>	4,816,570	3/28/89	Farquhar	536/27	
<i>msla</i>	4,968,788	11/6/90	Farquhar	536/27	1/23/89
<i>msla</i>	5,142,051	8/25/92	Holy et al	544/244	7/17/87
<i>msla</i>	5,177,064	1/5/93	Bodor	—	7/13/90
<i>msla</i>	5,208,221	5/4/93	Kim et al	514/81	11/29/90
<i>msla</i>	5,386,030	1/31/95	Kim et al	544/243	2/11/93
<i>msla</i>	5,506,347	4/9/96	Erion et al	—	2/3/94
<i>msla</i>	5,512,596	4/30/96	Kim et al.	514/568	9/2/94
<i>msla</i>	5,514,798	5/7/96	Bischofberger et al.	—	2/13/95
<i>msla</i>	5,618,964	4/8/97	Cheng et al.	—	6/7/95

FOREIGN PATENT DOCUMENTS

EXAMR'S INITIALS	PATENT NO.	PUBLICATION DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES/NO
<i>msla</i>	0 269 947 A1	6/8/88	EUROPE	—	
<i>msla</i>	0 369 409 A1	5/23/90	EUROPE	—	
<i>msla</i>	0 481 214 A1	4/22/92	EUROPE	—	
<i>msla</i>	0 632 048 A1	6/23/94	EUROPE	—	
<i>msla</i>	DE 41 38 584	5/27/93	GERMANY	—	
<i>msla</i>	EP 0 647 649 A1	4/12/95	EUROPE	—	
<i>msla</i>	WO 88/05438	7/28/88	PCT	—	
<i>msla</i>	WO 91/19721	12/26/91	PCT	—	
<i>msla</i>	WO 92/01698	2/6/92	PCT	—	
<i>msla</i>	WO 92/09611	6/11/92	PCT	—	

EXAMINER

Michael G. Ambrose

DATE CONSIDERED

4/2/98

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))	ATTY DOCKET NO.: 221.P1	SERIAL NO.: 08/900,746
	APPLICANT: Arimilli et al.	
	FILING DATE: 7/25/97	GROUP ART UNIT: 1613

EXAMR'S INITIALS	PATENT NO.	PUBLICATION DATE	COUNTRY	CLASS/SUBCLASS	TRANSLATION YES/NO
mscl	WO 92/13869	8/20/92	PCT	—	
mscl	WO 94/03466	2/17/94	PCT	—	
mscl	WO 94/03467	2/17/94	PCT	—	
mscl	WO 95/07919	3/23/95	PCT	—	
mscl	WO 95/07920	3/23/95	PCT	—	
mscl	WO 96/18605	6/20/96	PCT	—	

OTHER DOCUMENTS

EXAMR'S INITIALS	ARTICLE	
mscl	Alexander et al., "Investigation of (Oxodioxolenyl)methyl Carbamates as Nonchiral Bioreversible Prodrug Moieties for Chiral Amines", 39:480-486, J MED CHEM, 1996	✓
mscl	Benzaria et al., "New Prodrugs of 9-(2-Phosphonomethoxyethyl) Adenine [PMEA]: Synthesis and Stability Studies", 14(3-5):563-565, NUCLS & NUCLT, 1995	✓
mscl	Cannon, Joseph G. (Reviewer), "The Chemistry of the Carbonyl Group", Vol. II, Edited by Saul Patai, Book Review, Sep-1966	?
mscl	Davidson et al., "N-(Acyloxyalkyl)pyridinium Salts as Soluble Prodrugs of a Potent Platelet Activating Factor Antagonist", 37(26):4423-4429, J MED CHEM, 23-Dec-1994	✓
mscl	Engel, R., "Phosphonates as Analogues of Natural Phosphates", 77(3):349-367, CHEM REV, 1977	✓
mscl	Farquhar et al., "Biologically Reversible Phosphate-Protective Groups", 72:324-325, J PHARM SCI, 1983	✓
mscl	Flaherty et al., "Synthesis and Selective Monoamine Oxidase B-Inhibiting Properties of 1-Methyl-1,2,3,6-tetrahydropyrid-4-yl Carbamate Derivatives: Potential Prodrugs of (R)- and (S)-Nordeprenyl", 39:4759-4761, J MED CHEM, 1996	✓
mscl	Folkman et al., "Acyloxymethyl Carbonochloridates. New Intermediates in Prodrug Synthesis", pp. 1159-1166, SYNTHESIS, Dec-1990	✓
mscl	Hammer et al., "Ether, Carbonate and Urethane Deoxynucleoside Derivatives as Prodrugs", 50:609-622, Acta Chemica Scandinavia, 1996	✓
mscl	Ikeda et al., "Studies on Prodrugs. III. A Convenient and Practical Preparation of Ampicillin Prodrugs", 32:4316-4322, CHEM PHARM BULL, 1984	?
mscl	Iyer et al., "Synthesis of Acyloxyalkyl Acylphosphonates as Potential Prodrugs of the Antiviral, Trisodium Phosphonoformate (Foscarnet Sodium)", 30(51):7141-7144, TET LETT, 1989	✓
mscl	Lindahl et al., "Synthesis of an Acyloxymethyl Prodrug of the Inositol Phosphate Alpha-Trinositol", 15(5):549-554, J CARBOHYDRATE CHEMISTRY, 1996	✓

EXAMINER	Michael G. Ambrose	DATE CONSIDERED	4/2/98
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(37 CFR 1.98(b))</small>	ATTY DOCKET NO.: 221.P1 SERIAL NO.: 08/900,746
	APPLICANT: Arimilli et al.
	FILING DATE: 7/25/97 GROUP ART UNIT: 1413

EXAMR'S INITIALS	ARTICLE	
msca	Maillard et al., "Adenosine Receptor Prodrugs: Synthesis and Biological Activity of Derivatives of Potent, A1-Selective Agonists", 83(1):46-53, J PHARM SCI, Jan-1994	✓
msca	Myerson, Allan S. (editor), "Solutions and Solution Properties", p. 1 - 165, Handbook of Industrial Crystallization, 1993	✓
msca	Naesens et al., "Antiretroviral Activity and Pharmacokinetics in Mice of Oral Bis(Pivaloyloxymethyl)-9-(2-Phosphonylmethoxyethyl)Adenine, the Bis(Pivaloyloxymethyl) Ester Prodrug of 9-(2-Phosphonylmethoxyethyl)Adenine", 40(1):22-28, ANTIMICRO AG & CHEMO, Jan-1996	✓
msca	Robinson et al., "Discovery of the Hemifumarate and (alpha-L-Alanyloxy)methyl Ether as Prodrugs of an Antirheumatic Oxindole: Prodrugs for the Enolic OH Group", 39:10-18, J MED CHEM, 1996	✓
msca	Safadi et al., "Phosphoryloxymethyl Carbamates and Carbonates--Novel Water-Soluble Prodrugs for Amines and Hindered Alcohols", 10(9):1350-1355, PHARM RES, 1993	✓
msca	Sakamoto et al., "Studies on Prodrugs. II. Preparation and Characterization of (5-Substituted 2-Oxo-1,3-dioxolen-4-yl)methyl Esters of Ampicillin", 32(6):2241-2248, CHEM PHARM BULL, 19-Aug-1983	✓
msca	Samara et al., "Pharmacokinetic Analysis of Diethylcarbonate Prodrugs of Ibuprofen and Naproxen", 16:201-210, Biopharmaceutics & Drug Disposition, 1995	✓
msca	Srinivas et al., "Metabolism and In Vitro Antiretroviral Activities of Bis(Pivaloyloxymethyl) Prodrugs of Acyclic Nucleoside Phosphonates", 37(10):2247-2250, ANTIMICRO AG & CHEMO, Oct-1993	✓
msca	Srivastva et al., "Bioreversible Phosphate Protective Groups: Synthesis and Stability of Model Acyloxymethyl Phosphates", 12:118-129, BIOORG CHEM, 1984	✓
msca	Starrett et al., "Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl) 9-(2-phosphonylmethoxyethyl)adenine", 19:267-273, ANTIVIRAL RES, 1992	✓
msca	Sueoka et al., "Pharmacokinetics of Alkoxy carbonyloxy Ester Prodrugs of PMPA in Dogs", Abstract, American Association of Pharmaceutical Science, Western Regional Meeting, April 24-25, 1997,	?
msca	Sueoka et al., "Pharmacokinetics of Alkoxy carbonyloxy Ester Prodrugs of PMPA in Dogs", Poster, American Association of Pharmaceutical Science, Western Regional Meeting, April 24-25, 1997,	?
msca	Weller et al., "Orally Active Fibrinogen Receptor Antagonists. 2. Amidoximes a Prodrugs of Amidines", 39:3139-3147, J MED CHEM, 20-Dec-1995	✓

EXAMINER	Michael G. Ambrose	DATE CONSIDERED	4/2/98
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			